Who owns Beta Bionics Inc, from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Farallon Capital Management, L.L.C.: 1.3% · 595,000 shares — Zone Healthcare Holdings, LLC: 0.0% · 0 shares — Farallon Capital Partners, L.P.: 0.0% · 0 shares
Divisadero Street Capital Management, LP: 6.9% · 3,072,985 shares — William Zolezzi: 6.9% · 3,072,985 shares — Divisadero Street Partners, L.P.: 5.9% · 2,612,985 shares
15 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Beta Bionics Inc.
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Beta Bionics Inc they hold. Together these 201 managers report 124.08% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| EVENTIDE ASSET MANAGEMENT, LLC | $98.1M | 6,253,673 | 1.31% | 13.90% | June 30, 2026 |
| Soleus Capital Management, L.P. | $68.8M | 4,393,714 | 2.37% | 9.77% | June 30, 2026 |
199 more institutional holders behind a free account
See every manager reporting Beta Bionics Inc, how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 150 funds hold 30.66% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| Eventide Gilead Fund | $62.4M | 1.81% | 8.86% | June 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | $32.2M | 1.80% | 4.56% | June 30, 2026 |
148 more funds behind a free account
See every fund holding Beta Bionics Inc and what share of its net assets the position represents.
Sign up freeLoading...
